OMER
OMEROS CORP
NASDAQ · Healthcare · Biotechnology · US
$17.87
−3.14%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.05
- Revenue estimate
- $36.7M
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- $0.15
- EPS estimate
- -$0.27
- Revenue actual
- $28.5M
- Revenue estimate
- $12.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +233.5%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.27 | $0.15 | Beat 155.91% | $28.5M |
| May 13, 2026 | -$0.40 | -$0.24 | Beat 40.00% | $9.9M |
| Mar 31, 2026 | -$0.55 | $3.14 | Beat 670.91% | — |
| Nov 13, 2025 | -$0.58 | -$0.19 | Beat 67.24% | — |
| Aug 14, 2025 | -$0.55 | -$0.53 | Beat 3.64% | — |
| May 15, 2025 | -$0.57 | -$0.65 | Miss -14.04% | — |
| Mar 31, 2025 | -$0.78 | -$0.63 | Beat 19.23% | $412.0K |
| May 15, 2024 | -$0.58 | -$0.74 | Miss -27.59% | — |
| Nov 9, 2023 | -$0.62 | -$0.82 | Miss -32.26% | — |
| Mar 13, 2023 | -$0.57 | -$0.73 | Miss -28.07% | — |
| Mar 1, 2022 | -$0.30 | -$0.37 | Miss -23.33% | $79.9M |
| Mar 1, 2021 | -$0.64 | -$0.54 | Beat 15.62% | $10.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026